Find Pharmaceutical Logo stock video, 4K footage, and other HD footage from iStock. Get higher quality Pharmaceutical Logo content, for less—All of our 4K video clips are the same price as HD. Video ...

Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million for the quarter, compared to the consensus ...

Rhythm Pharmaceuticals (RYTM) and the Raymond A. Wood Foundation announced a new research collaboration to study the impact of fatigue on ...

Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...

BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...

Rhythm Pharmaceuticals RYTM has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ...

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...

10 analysts have shared their evaluations of Rhythm Pharmaceuticals (NASDAQ:RYTM) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

Rhythm Pharmaceuticals has a twelve month low of $35.17 and a twelve month high of $68.58. The company has a market capitalization of $3.38 billion, a PE ratio of -12.35 and a beta of 2.30. Hedge ...

BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...

Rhythm Pharmaceuticals received an orphan-drug designation from Japan's Ministry of Health, Labour and Welfare for its treatment for a certain type of obesity. The Boston-based biopharmaceutical ...

BOSTON - Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company specializing in rare neuroendocrine diseases with a current market capitalization of $3.51 billion and impressive ...